cmcmaster/rheumatology-biologics-dataset · Datasets at Hugging Face

pbs_code stringlengths 5 6	drug stringclasses 17 values	brand stringclasses 30 values	formulation stringclasses 37 values	indication stringclasses 8 values	treatment_phase stringclasses 57 values	streamlined_code stringclasses 33 values	online_application bool 2 classes	authority_method stringclasses 2 values	hospital_type stringclasses 3 values	schedule_code int64 3.47k 3.47k	schedule_year int64 2.02k 2.02k	schedule_month stringclasses 1 value
12406Y	adalimumab	Humira	Injection 20 mg in 0.2 mL pre-filled syringe	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12406Y	adalimumab	Humira	Injection 20 mg in 0.2 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12406Y	adalimumab	Humira	Injection 20 mg in 0.2 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13763J	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13763J	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13763J	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13763J	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13763J	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13763J	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13763J	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13763J	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13763J	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled syringe	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
14589W	bimekizumab	Bimzelx	Injection 160 mg in 1 mL single use pre-filled pen	non-radiographic axial spondyloarthritis	Continuing treatment	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
14589W	bimekizumab	Bimzelx	Injection 160 mg in 1 mL single use pre-filled pen	non-radiographic axial spondyloarthritis	Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
14589W	bimekizumab	Bimzelx	Injection 160 mg in 1 mL single use pre-filled pen	non-radiographic axial spondyloarthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13292N	adalimumab	Humira	Injection 20 mg in 0.2 mL pre-filled syringe	juvenile idiopathic arthritis	Continuing treatment	14107	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
11326D	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13700C	infliximab	Inflectra	Powder for I.V. infusion 100 mg	rheumatoid arthritis	First continuing treatment	14585	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
13700C	infliximab	Renflexis	Powder for I.V. infusion 100 mg	rheumatoid arthritis	First continuing treatment	14585	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
11322X	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11322X	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11322X	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
14125K	upadacitinib	Rinvoq	Tablet 15 mg	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12568L	guselkumab	Tremfya	Injection 100 mg in 1 mL single use pre-filled pen	psoriatic arthritis	Continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12568L	guselkumab	Tremfya	Injection 100 mg in 1 mL single use pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12568L	guselkumab	Tremfya	Injection 100 mg in 1 mL single use pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12568L	guselkumab	Tremfya	Injection 100 mg in 1 mL single use pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12568L	guselkumab	Tremfya	Injection 100 mg in 1 mL single use pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12568L	guselkumab	Tremfya	Injection 100 mg in 1 mL single use pre-filled pen	psoriatic arthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5735W	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5735W	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5735W	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5735W	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12327T	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	ankylosing spondylitis	First continuing treatment	14683	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12327T	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	ankylosing spondylitis	First continuing treatment	14683	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12327T	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	ankylosing spondylitis	First continuing treatment	14683	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12327T	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled syringe	ankylosing spondylitis	First continuing treatment	14683	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12327T	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	ankylosing spondylitis	Subsequent continuing treatment	14701	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12327T	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	ankylosing spondylitis	Subsequent continuing treatment	14701	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12327T	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	ankylosing spondylitis	Subsequent continuing treatment	14701	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12327T	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled syringe	ankylosing spondylitis	Subsequent continuing treatment	14701	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13703F	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	14567	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13703F	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	14567	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13703F	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled pen	rheumatoid arthritis	First continuing treatment	14567	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
10898N	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13689L	baricitinib	Olumiant	Tablet 2 mg	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
11201M	etanercept	Enbrel	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
11201M	etanercept	Brenzys	Injection 50 mg in 1 mL single use auto-injector, 4	ankylosing spondylitis	Subsequent continuing treatment	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
14235F	adalimumab	Abrilada	Injection 20 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
14235F	adalimumab	Abrilada	Injection 20 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
14235F	adalimumab	Abrilada	Injection 20 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
14235F	adalimumab	Abrilada	Injection 20 mg in 0.4 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
12577Y	infliximab	Remsima SC	Solution for injection 120 mg in 1 mL pre-filled pen	rheumatoid arthritis	Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12326R	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12326R	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12326R	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
12326R	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled syringe	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13705H	abatacept	Orencia	Powder for I.V. infusion 250 mg	rheumatoid arthritis	Subsequent continuing treatment	14555	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
12297F	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	non-radiographic axial spondyloarthritis	Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
12297F	secukinumab	Cosentyx	Injection 150 mg in 1 mL pre-filled pen	non-radiographic axial spondyloarthritis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
5753T	infliximab	Remicade	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Inflectra	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Renflexis	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Remicade	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Inflectra	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Renflexis	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Remicade	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Inflectra	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Renflexis	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Remicade	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Inflectra	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Renflexis	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Remicade	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Inflectra	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Renflexis	Powder for I.V. infusion 100 mg	ankylosing spondylitis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Remicade	Powder for I.V. infusion 100 mg	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Inflectra	Powder for I.V. infusion 100 mg	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
5753T	infliximab	Renflexis	Powder for I.V. infusion 100 mg	ankylosing spondylitis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Public	3,471	2,024	NOVEMBER
13214L	adalimumab	Hadlima	Injection 40 mg in 0.4 mL pre-filled pen	psoriatic arthritis	Subsequent continuing treatment	11523	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13214L	adalimumab	Yuflyma	Injection 40 mg in 0.4 mL pre-filled pen	psoriatic arthritis	Subsequent continuing treatment	11523	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13214L	adalimumab	Adalicip	Injection 40 mg in 0.4 mL pre-filled pen	psoriatic arthritis	Subsequent continuing treatment	11523	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
13701D	certolizumab pegol	Cimzia	Solution for injection 200 mg in 1 mL pre-filled pen	rheumatoid arthritis	Subsequent continuing treatment	14499	true	STREAMLINED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply	null	true	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
9101B	adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	psoriatic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)	null	false	AUTHORITY_REQUIRED	Any	3,471	2,024	NOVEMBER
13731Q	tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	Subsequent continuing treatment	14485	true	STREAMLINED	Private	3,471	2,024	NOVEMBER
6496X	infliximab	Remicade	Powder for I.V. infusion 100 mg	psoriatic arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Private	3,471	2,024	NOVEMBER

12406Y

adalimumab

Humira

Injection 20 mg in 0.2 mL pre-filled syringe

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12406Y

adalimumab

Humira

Injection 20 mg in 0.2 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12406Y

adalimumab

Humira

Injection 20 mg in 0.2 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13763J

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13763J

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13763J

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13763J

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13763J

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13763J

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13763J

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13763J

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13763J

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled syringe

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

14589W

bimekizumab

Bimzelx

Injection 160 mg in 1 mL single use pre-filled pen

non-radiographic axial spondyloarthritis

Continuing treatment

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

14589W

bimekizumab

Bimzelx

Injection 160 mg in 1 mL single use pre-filled pen

non-radiographic axial spondyloarthritis

Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

14589W

bimekizumab

Bimzelx

Injection 160 mg in 1 mL single use pre-filled pen

non-radiographic axial spondyloarthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13292N

adalimumab

Humira

Injection 20 mg in 0.2 mL pre-filled syringe

juvenile idiopathic arthritis

Continuing treatment

14107

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

11326D

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13700C

infliximab

Inflectra

Powder for I.V. infusion 100 mg

rheumatoid arthritis

First continuing treatment

14585

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

13700C

infliximab

Renflexis

Powder for I.V. infusion 100 mg

rheumatoid arthritis

First continuing treatment

14585

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

11322X

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11322X

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11322X

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

14125K

upadacitinib

Rinvoq

Tablet 15 mg

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12568L

guselkumab

Tremfya

Injection 100 mg in 1 mL single use pre-filled pen

psoriatic arthritis

Continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12568L

guselkumab

Tremfya

Injection 100 mg in 1 mL single use pre-filled pen

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12568L

guselkumab

Tremfya

Injection 100 mg in 1 mL single use pre-filled pen

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12568L

guselkumab

Tremfya

Injection 100 mg in 1 mL single use pre-filled pen

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12568L

guselkumab

Tremfya

Injection 100 mg in 1 mL single use pre-filled pen

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12568L

guselkumab

Tremfya

Injection 100 mg in 1 mL single use pre-filled pen

psoriatic arthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5735W

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5735W

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5735W

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5735W

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12327T

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

ankylosing spondylitis

First continuing treatment

14683

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12327T

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

ankylosing spondylitis

First continuing treatment

14683

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12327T

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

ankylosing spondylitis

First continuing treatment

14683

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12327T

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled syringe

ankylosing spondylitis

First continuing treatment

14683

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12327T

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

ankylosing spondylitis

Subsequent continuing treatment

14701

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12327T

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

ankylosing spondylitis

Subsequent continuing treatment

14701

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12327T

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

ankylosing spondylitis

Subsequent continuing treatment

14701

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12327T

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled syringe

ankylosing spondylitis

Subsequent continuing treatment

14701

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13703F

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled pen

rheumatoid arthritis

First continuing treatment

14567

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13703F

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled pen

rheumatoid arthritis

First continuing treatment

14567

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13703F

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled pen

rheumatoid arthritis

First continuing treatment

14567

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

10898N

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13689L

baricitinib

Olumiant

Tablet 2 mg

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

11201M

etanercept

Enbrel

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

11201M

etanercept

Brenzys

Injection 50 mg in 1 mL single use auto-injector, 4

ankylosing spondylitis

Subsequent continuing treatment

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

14235F

adalimumab

Abrilada

Injection 20 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

14235F

adalimumab

Abrilada

Injection 20 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

14235F

adalimumab

Abrilada

Injection 20 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

14235F

adalimumab

Abrilada

Injection 20 mg in 0.4 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

12577Y

infliximab

Remsima SC

Solution for injection 120 mg in 1 mL pre-filled pen

rheumatoid arthritis

Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12326R

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12326R

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12326R

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

12326R

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled syringe

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13705H

abatacept

Orencia

Powder for I.V. infusion 250 mg

rheumatoid arthritis

Subsequent continuing treatment

14555

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

12297F

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

non-radiographic axial spondyloarthritis

Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

12297F

secukinumab

Cosentyx

Injection 150 mg in 1 mL pre-filled pen

non-radiographic axial spondyloarthritis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

5753T

infliximab

Remicade

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Inflectra

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Renflexis

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Remicade

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Inflectra

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Renflexis

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Remicade

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Inflectra

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Renflexis

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Remicade

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Inflectra

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Renflexis

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Remicade

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Inflectra

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Renflexis

Powder for I.V. infusion 100 mg

ankylosing spondylitis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Remicade

Powder for I.V. infusion 100 mg

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Inflectra

Powder for I.V. infusion 100 mg

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

5753T

infliximab

Renflexis

Powder for I.V. infusion 100 mg

ankylosing spondylitis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Public

3,471

2,024

NOVEMBER

13214L

adalimumab

Hadlima

Injection 40 mg in 0.4 mL pre-filled pen

psoriatic arthritis

Subsequent continuing treatment

11523

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13214L

adalimumab

Yuflyma

Injection 40 mg in 0.4 mL pre-filled pen

psoriatic arthritis

Subsequent continuing treatment

11523

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13214L

adalimumab

Adalicip

Injection 40 mg in 0.4 mL pre-filled pen

psoriatic arthritis

Subsequent continuing treatment

11523

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

13701D

certolizumab pegol

Cimzia

Solution for injection 200 mg in 1 mL pre-filled pen

rheumatoid arthritis

Subsequent continuing treatment

14499

true

STREAMLINED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

null

true

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

9101B

adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

psoriatic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)

null

false

AUTHORITY_REQUIRED

Any

3,471

2,024

NOVEMBER

13731Q

tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

Subsequent continuing treatment

14485

true

STREAMLINED

Private

3,471

2,024

NOVEMBER

6496X

infliximab

Remicade

Powder for I.V. infusion 100 mg

psoriatic arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Private

3,471

2,024

NOVEMBER